Literature DB >> 24485876

Immunotherapy for solid tumors--a review for surgeons.

Abdul Saied1, Venu G Pillarisetty2, Steven C Katz3.   

Abstract

Immunotherapy has evolved considerably in the last decade and is becoming an integral component of the armamentarium for the treatment of patients with advanced solid tumors. It is important for clinicians, especially surgeons, to understand the basic principles of novel immunotherapies and the immune system. This review summarizes the evolution of the most relevant immunotherapies, their mechanisms of action, the data supporting their clinical use, and integration of immunotherapy into multidisciplinary management of solid tumors. This review should serve as a primer for clinicians and surgeons to understand the rapidly evolving field of immunotherapy.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Adoptive cell transfer therapy; Immunotherapy; Solid tumors

Mesh：

Substances：

Year:  2013        PMID： 24485876      PMCID： PMC4044916          DOI： 10.1016/j.jss.2013.12.018

Source DB:  PubMed          Journal:  J Surg Res        ISSN： 0022-4804            Impact factor:   2.192


  93 in total

1.  Association of enhanced cyclooxygenase-2 expression with possible local immunosuppression in human colorectal carcinomas.

Authors:  M Kojima; T Morisaki; A Uchiyama; F Doi; R Mibu; M Katano; M Tanaka
Journal:  Ann Surg Oncol       Date:  2001-06       Impact factor: 5.344

2.  Fas-mediated suicide of tumor-reactive T cells following activation by specific tumor: selective rescue by caspase inhibition.

Authors:  T Z Zaks; D B Chappell; S A Rosenberg; N P Restifo
Journal:  J Immunol       Date:  1999-03-15       Impact factor: 5.422

3.  PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors.

Authors:  Michael A Curran; Welby Montalvo; Hideo Yagita; James P Allison
Journal:  Proc Natl Acad Sci U S A       Date:  2010-02-16       Impact factor: 11.205

4.  Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an open-label, multicenter phase I/II study.

Authors:  S F Slovin; C S Higano; O Hamid; S Tejwani; A Harzstark; J J Alumkal; H I Scher; K Chin; P Gagnier; M B McHenry; T M Beer
Journal:  Ann Oncol       Date:  2013-03-27       Impact factor: 32.976

Review 5.  IDO expression by dendritic cells: tolerance and tryptophan catabolism.

Authors:  Andrew L Mellor; David H Munn
Journal:  Nat Rev Immunol       Date:  2004-10       Impact factor: 53.106

6.  Modulation of tryptophan catabolism by regulatory T cells.

Authors:  Francesca Fallarino; Ursula Grohmann; Kwang Woo Hwang; Ciriana Orabona; Carmine Vacca; Roberta Bianchi; Maria Laura Belladonna; Maria Cristina Fioretti; Maria-Luisa Alegre; Paolo Puccetti
Journal:  Nat Immunol       Date:  2003-10-26       Impact factor: 25.606

7.  Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2.

Authors:  S A Rosenberg; J C Yang; S L Topalian; D J Schwartzentruber; J S Weber; D R Parkinson; C A Seipp; J H Einhorn; D E White
Journal:  JAMA       Date:  1994 Mar 23-30       Impact factor: 56.272

8.  Nivolumab plus ipilimumab in advanced melanoma.

Authors:  Jedd D Wolchok; Harriet Kluger; Margaret K Callahan; Michael A Postow; Naiyer A Rizvi; Alexander M Lesokhin; Neil H Segal; Charlotte E Ariyan; Ruth-Ann Gordon; Kathleen Reed; Matthew M Burke; Anne Caldwell; Stephanie A Kronenberg; Blessing U Agunwamba; Xiaoling Zhang; Israel Lowy; Hector David Inzunza; William Feely; Christine E Horak; Quan Hong; Alan J Korman; Jon M Wigginton; Ashok Gupta; Mario Sznol
Journal:  N Engl J Med       Date:  2013-06-02       Impact factor: 91.245

9.  Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer.

Authors:  Lin Zhang; Jose R Conejo-Garcia; Dionyssios Katsaros; Phyllis A Gimotty; Marco Massobrio; Giorgia Regnani; Antonis Makrigiannakis; Heidi Gray; Katia Schlienger; Michael N Liebman; Stephen C Rubin; George Coukos
Journal:  N Engl J Med       Date:  2003-01-16       Impact factor: 91.245

10.  Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells.

Authors:  Luca Gattinoni; Steven E Finkelstein; Christopher A Klebanoff; Paul A Antony; Douglas C Palmer; Paul J Spiess; Leroy N Hwang; Zhiya Yu; Claudia Wrzesinski; David M Heimann; Charles D Surh; Steven A Rosenberg; Nicholas P Restifo
Journal:  J Exp Med       Date:  2005-10-03       Impact factor: 14.307
View more
  9 in total

Review 1.  Intraperitoneal immunotherapy: historical perspectives and modern therapy.

Authors:  W F Morano; A Aggarwal; P Love; S D Richard; J Esquivel; W B Bowne
Journal:  Cancer Gene Ther       Date:  2016-11-11       Impact factor: 5.987

Review 2.  The prognostic value of liver tumor T cell infiltrates.

Authors:  Hadi Khan; Venu G Pillarisetty; Steven C Katz
Journal:  J Surg Res       Date:  2014-06-07       Impact factor: 2.192

Review 3.  Soft tissue sarcomas in the precision medicine era: new advances in clinical practice and future perspectives.

Authors:  Giuseppe Badalamenti; Carlo Messina; Ida De Luca; Emmanuela Musso; Alessandra Casarin; Lorena Incorvaia
Journal:  Radiol Med       Date:  2018-04-04       Impact factor: 3.469

4.  Cancer immunotherapy in clinical practice -- the past, present, and future.

Authors:  Gaurav Goel; Weijing Sun
Journal:  Chin J Cancer       Date:  2014-09

5.  Neutrophil:lymphocyte ratios and serum cytokine changes after hepatic artery chimeric antigen receptor-modified T-cell infusions for liver metastases.

Authors:  A Saied; L Licata; R A Burga; M Thorn; E McCormack; B F Stainken; E O Assanah; P D Khare; R Davies; N J Espat; R P Junghans; S C Katz
Journal:  Cancer Gene Ther       Date:  2014-10-03       Impact factor: 5.987

6.  Regional CAR-T cell infusions for peritoneal carcinomatosis are superior to systemic delivery.

Authors:  S C Katz; G R Point; M Cunetta; M Thorn; P Guha; N J Espat; C Boutros; N Hanna; R P Junghans
Journal:  Cancer Gene Ther       Date:  2016-04-15       Impact factor: 5.987

7.  Hydrothermal synthesis, characterization and enhanced photocatalytic activity and toxicity studies of a rhombohedral Fe2O3 nanomaterial.

Authors:  Mavinakere Ramesh Abhilash; Akshatha Gangadhar; Jagadish Krishnegowda; Mahendra Chikkamadaiah; Shivanna Srikantaswamy
Journal:  RSC Adv       Date:  2019-08-13       Impact factor: 4.036

Review 8.  Challenges in assessing solid tumor responses to immunotherapy.

Authors:  Louis F Chai; Ethan Prince; Venu G Pillarisetty; Steven C Katz
Journal:  Cancer Gene Ther       Date:  2019-12-11       Impact factor: 5.987

9.  A New Concept of Enhancing Immuno-Chemotherapeutic Effects Against B16F10 Tumor via Systemic Administration by Taking Advantages of the Limitation of EPR Effect.

Authors:  Yuting Yang; Xiaowei Tai; Kairong Shi; Shaobo Ruan; Yue Qiu; Zhirong Zhang; Bing Xiang; Qin He
Journal:  Theranostics       Date:  2016-09-12       Impact factor: 11.556
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.